

Press release
Paris, October 25, 2017

Keensight Capital to reinvest in Menix, a reference player in orthopedic prostheses and dental implants solutions

Keensight Capital, one of the leading players in European Growth Private Equity¹, announced that it would reinvest in Menix, a French leader in hip prosthesis and a major player in dental implants solutions, alongside the Company's management team, led by Patrick Rondot, Jean-Luc Aurelle and Christophe Marrone, Five Arrows Principal Investments and Turenne Capital.

Based in Lyon and armed with 340 employees, Menix has an unparalleled reputation and trademark image on the worldwide orthopedics market, notably thanks to an undisputed leadership position in the high growth niche segment of dual mobility hip prosthesis, in France and internationally. The concept of dual mobility cup, which was invented and developed by the Company, enables to reduce significantly the dislocation risk linked to hip replacement surgery. Menix has also developed leading positions in dental implants and Cranio-Maxillo-Facial surgery in France. Renowned for its brand names Serf, Dedienne, and Global D, synonymous with quality and innovation in orthopedic prostheses and dental implants, Menix has significantly strengthened its product ranges over the last three years, through major internal developments as well as through external growth with the acquisitions of Transystème and OneOrtho.

Experiencing a 15% compound annual revenue growth over the past years, Menix plans to continue its development, notably by extending its product offering with the launch of a new range of knee prostheses, by accelerating international sales growth, as well as through new targeted acquisitions in France and in Europe.

Patrick Rondot, CEO of Menix, commented: *"We are delighted to be joining forces with Five Arrows Principal Investments, which has demonstrated a deep understanding of our business sector and our key differentiating assets. We want to thank Keensight Capital for their renewed trust in our onward journey. Thanks to its thorough knowledge and expertise in orthopedics, Keensight has played a decisive role as supportive shareholder with strong value-added impact."*

Pierre Rémy, Managing Partner at Keensight Capital, added: *"We are pleased to see Menix embarking on a new and exciting phase of its development. During our 3-year tenure as shareholder, the Company has strengthened its leadership position in orthopedics and has substantially grown its presence in dental implants solutions; a string of successes which have been achieved by a high-caliber management team. By reinvesting in Menix, we remain committed to support Patrick Rondot and his team in achieving ambitious growth plans, both organically notably with the launch of a new complete set of knee implants, and through external growth."*

¹ **Growth Private Equity:** investment in profitable, private companies experiencing strong growth, in minority or majority positions, with or without leverage, using a flexible approach adapted to the needs of individual entrepreneurs, in order to finance organic growth projects, acquisition strategies or provide historic shareholders with liquidity.

Parties involved in the transaction:

- Team at Keensight Capital: Pierre REMY, Jaana GRUTER, David PICCOLI

About Menix Group

MENIX Group operates as a French holding company with leadership positions in surgical orthopedic prostheses and dental implants, as well Cranio-Maxillo-Facial surgery. In less than 10 years, MENIX Group revenues have multiplied by 10 and continue to generate a double-digit organic annual growth. The group has 340 employees and recorded revenues of €67m in 2016. The Management team is led by Patrick Rondot, Jean-Luc Aurelle and Christophe Marrone. www.dediennesante.com

About Keensight Capital

Keensight Capital, one of the leading European Growth Private Equity firms, is committed to supporting entrepreneurs as they implement their growth strategies. For almost 20 years now, our team of seasoned professionals have leveraged their knowledge in investment and growth industries to invest for the long term in profitable companies with high growth potential and revenues in the range of €15 million to €250 million.

Drawing on our expertise in a variety of sectors including Internet/Media, Information Technology, Healthcare and Services, we identify the best investment opportunities in Europe and work closely with management teams to develop and achieve their strategic vision. www.keensightcapital.com

Press Contacts

Anne de Bonnefon - abonnefon@keensightcapital.com - +33 1 83 79 87 37

Citigate Dewe Rogerson - Robert Amady – robert.amady@citigate.fr - +33 1 53 32 78 91